Marco Mantoan

Dr. Marco Mantoan

Department of Diagnostics and Public Health, University of Verona, Verona, Veneto, Italy
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Erica DianiErica Diani
Erica Diani
RCRiccardo Cecchetto
Riccardo Cecchetto
ETEmil Tonon
Emil Tonon
MMMarco Mantoan
Marco Mantoan
VLVirginia Lotti
Virginia Lotti
DGDavide Gibellini
Davide Gibellini
Omsk hemorrhagic fever virus (OHFV) is the etiological agent of a poorly studied acute viral disease, causing several epidemic waves observed in the western Siberia regions of Omsk, Kurgan, Novosibirsk, and Tyumen. OHFV is a flavivirus and shares structural and morphological features with tick-borne encephalitis (TBE) complex viruses. The disease’s symptoms show high variability, from flu-like symptoms, hyperesthesia, and petechial rush in the upper body to high fever and hemorrhagic manifestations, with a fatality rate of about 1%. The real number of OHFV-infected people is still unknown due to the difficulties in diagnosis and the presence of asymptomatic patients that lead to an underestimation of the total cases. Little is known about the viral infection dynamics at the molecular and cellular levels, the viral involvement in immune escape, cellular pathways alteration, or metabolic influence. It is noteworthy that no clinical trials have currently been performed for effective and specific drug treatments. In this review, we will give an overview of OHFV interactions with humans and animals, diagnostic tools, and drug treatments. We aim to highlight the importance of a frequently undiagnosed or misdiagnosed viral infection that might also even cause severe clinical manifestations such as meningitis and hemorrhage, in order to point out the need to develop new research studies, new diagnostic tools, and new treatments for OHFV.

Verified
Journal Article
Open access
PDF file
RCRiccardo Cecchetto
Riccardo Cecchetto
ETEmil Tonon
Emil Tonon
APAsia Palmisano
Asia Palmisano
ALAnna Lagni
Anna Lagni
Erica DianiErica Diani
Erica Diani
DGDavide Gibellini
Davide Gibellini
The repeated occurrence of SARS-CoV-2 variants, largely driven by virus–host interactions, was and will remain a public health concern. Spike protein mutations shaped viral infectivity, transmissibility, and immune escape. From February 2022 to April 2024, a local genomic surveillance program in Verona, Italy, was conducted on 1333 SARS-CoV-2-positive nasopharyngeal swabs via next generation full-length genome sequencing. Spike protein mutations were classified based on their prevalence over time. Mutations were grouped into five categories: fixed, emerging, fading, transient, and divergent. Notably, some divergent mutations displayed a “Lazarus effect,” disappearing and later reappearing in new lineages, indicating potential adaptive advantages in specific genomic contexts. This two-year surveillance study highlights the dynamic nature of spike protein mutations and their role in SARS-CoV-2 evolution. The findings underscore the need for ongoing mutation-focused genomic monitoring to detect early signals of variant emergence, especially among mutations previously considered disadvantageous. Such efforts are critical for driving public health responses and guiding future vaccine and therapeutic strategies.

1 August 2026 in Gastroenterology Research
Verified
Journal Article
Open access
PDF file
MMMarco Mantoan
Marco Mantoan
ACAntonio Colantoni
Antonio Colantoni
ASAndrea Carlo Sironi
Andrea Carlo Sironi
VNValentina Nola
Valentina Nola
EAElena Aragona
Elena Aragona
SASalvatore Emanuele Aragona
Salvatore Emanuele Aragona
Background: Gastroesophageal reflux and acid-related symptoms substantially impair quality of life. Proton pump inhibitors (PPIs) remain the first-line therapy, but concerns regarding their long-term use and the persistence of symptoms in a significant proportion of patients highlight the need for complementary mucosal protection strategies. Real-world patient-reported outcomes (PROs) for barrier-forming medical devices (MDs) in individuals with reflux symptoms remain limited. Methods: An anonymous questionnaire was administered to 155 adults presenting with reflux-related symptoms. Assessments were conducted at baseline and after 7, 15, and 25 days of using the MD Piromal®. Symptom domains included typical reflux manifestations (heartburn, regurgitation, epigastric pain), atypical/extra-esophageal symptoms (sore throat, hoarseness, globus, throat clearing, supine cough), and dyspeptic symptoms (early satiety, postprandial fullness), rated using Likert-type severity (0–5) and frequency (0–4) scales. Nocturnal disturbances and quality-of-life impact (Verbal Numeric Rating Scale (VNRS) 0–10 for daily and social interference) were also evaluated. Changes over time were analyzed using Wilcoxon signed-rank tests. Exploratory comparisons between the MD alone (n = 133) and MD + PPI (n = 22) were performed using Wilcoxon rank-sum tests. Results: Participants had a mean age of 53.2 ± 16.7 years; 55.5% were female, and 85.8% reported predominantly typical reflux symptoms. All diurnal and nocturnal symptoms showed significant reductions at 25 days (severity/frequency P < 0.0001, except hoarseness P = 0.004), with progressive improvements observed at 7 and 15 days. Quality-of-life interference decreased markedly (daily: 7.90 ± 0.87 to 2.85 ± 1.16; social: 8.86 ± 0.89 to 2.74 ± 1.01; both P < 0.0001). Overall satisfaction was high, with 90.4% reporting outcomes exceeding expectations. The most frequently reported adverse events were nausea (23.9%) and flatulence (14.8%). Conclusions: In routine clinical practice, the use of MD was associated with substantial improvements in patient-reported upper gastrointestinal symptoms and quality-of-life measures over 25 days. Exploratory subgroup findings did not show a consistent advantage of adding PPIs across most symptom domains, suggesting that meaningful symptom relief was already observed with the MD alone in this survey. However, these findings should be interpreted as hypothesis-generating. Further controlled studies are needed to clarify the role of the MD within integrated management strategies for reflux-related symptoms.

13 November 2026 in Health Policy and Technology
Verified
Journal Article
Open access
SASimone Accordini
Simone Accordini
VLValentina Lando
Valentina Lando
LPLaura Portas
Laura Portas
LCLucia Calciano
Lucia Calciano
Roberto BonoRoberto Bono
Roberto Bono
Christer JansonChrister Janson
Christer Janson